193 related articles for article (PubMed ID: 8811211)
21. A comparison of bedside renal function estimates and measured glomerular filtration rate (Tc99mDTPA clearance) in cancer patients.
Poole SG; Dooley MJ; Rischin D
Ann Oncol; 2002 Jun; 13(6):949-55. PubMed ID: 12123341
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of serum iohexol clearance for use in predicting carboplatin clearance in cats.
Bailey DB; Rassnick KM; Prey JD; Dykes NL
Am J Vet Res; 2009 Sep; 70(9):1135-40. PubMed ID: 19719430
[TBL] [Abstract][Full Text] [Related]
23. Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing.
Ando Y; Minami H; Saka H; Ando M; Sakai S; Shimokata K
Br J Cancer; 1997; 76(8):1067-71. PubMed ID: 9376268
[TBL] [Abstract][Full Text] [Related]
24. Accurate determination of glomerular filtration rate in adults for carboplatin dosing: Moving beyond Cockcroft and Gault.
Tsang C; Akbari A; Frechette D; Brown PA
J Oncol Pharm Pract; 2021 Mar; 27(2):368-375. PubMed ID: 33297846
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of glomerular filtration rate estimation by Cockcroft-Gault, Jelliffe, Wright and Modification of Diet in Renal Disease (MDRD) formulae in oncology patients.
Ainsworth NL; Marshall A; Hatcher H; Whitehead L; Whitfield GA; Earl HM
Ann Oncol; 2012 Jul; 23(7):1845-53. PubMed ID: 22104575
[TBL] [Abstract][Full Text] [Related]
26. Derivation of new equations to estimate glomerular filtration rate in pediatric oncology patients.
Millisor VE; Roberts JK; Sun Y; Tang L; Daryani VM; Gregornik D; Cross SJ; Ward D; Pauley JL; Molinelli A; Brennan RC; Stewart CF
Pediatr Nephrol; 2017 Sep; 32(9):1575-1584. PubMed ID: 28573537
[TBL] [Abstract][Full Text] [Related]
27. Extension of the Calvert formula to patients with severe renal insufficiency.
Oguri T; Shimokata T; Ito I; Yasuda Y; Sassa N; Nishiyama M; Hamada A; Hasegawa Y; Ando Y
Cancer Chemother Pharmacol; 2015 Jul; 76(1):53-9. PubMed ID: 25957958
[TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function.
Duong JK; Veal GJ; Nath CE; Shaw PJ; Errington J; Ladenstein R; Boddy AV
Br J Clin Pharmacol; 2019 Jan; 85(1):136-146. PubMed ID: 30261554
[TBL] [Abstract][Full Text] [Related]
29. Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate.
Dooley MJ; Poole SG; Rischin D; Webster LK
Eur J Cancer; 2002 Jan; 38(1):44-51. PubMed ID: 11750838
[TBL] [Abstract][Full Text] [Related]
30. Serum cystatin C concentration compared with other markers of glomerular filtration rate in the old old.
Van Den Noortgate NJ; Janssens WH; Delanghe JR; Afschrift MB; Lameire NH
J Am Geriatr Soc; 2002 Jul; 50(7):1278-82. PubMed ID: 12133025
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin.
Holweger K; Lipp HP; Beijnen JH; Bokemeyer C; Hartmann JT
Cancer Chemother Pharmacol; 2011 Sep; 68(3):693-701. PubMed ID: 21136060
[TBL] [Abstract][Full Text] [Related]
32. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
Ekhart C; Rodenhuis S; Schellens JH; Beijnen JH; Huitema AD
Cancer Chemother Pharmacol; 2009 Jun; 64(1):115-22. PubMed ID: 18989671
[TBL] [Abstract][Full Text] [Related]
33. Estimation of glomerular filtration rate in children using 99m-technetium DTPA. A comparison with 51-chromium EDTA clearance.
Yap HK; Sundram FX; Yip WC; Tay JS; Ang ES; Toh HJ; Joseph VT; Saw AH
Acta Paediatr Scand; 1985 Jul; 74(4):579-83. PubMed ID: 3927656
[TBL] [Abstract][Full Text] [Related]
34. Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial.
Thomas H; Boddy AV; English MW; Hobson R; Imeson J; Lewis I; Morland B; Pearson AD; Pinkerton R; Price L; Stevens M; Newell DR
J Clin Oncol; 2000 Nov; 18(21):3614-21. PubMed ID: 11054434
[TBL] [Abstract][Full Text] [Related]
35. Comparison of methods of assessment of renal function in patients with cancer treated with cisplatin, carboplatin or methotrexate.
Robinson BA; Frampton CM; Colls BM; Atkinson CH; Fitzharris BM
Aust N Z J Med; 1990 Oct; 20(5):657-62. PubMed ID: 2285382
[TBL] [Abstract][Full Text] [Related]
36. A comparison of the predictive performance of different methods of kidney function estimation in a well-characterized HIV-infected population.
Barraclough K; Er L; Ng F; Harris M; Montaner J; Levin A
Nephron Clin Pract; 2009; 111(1):c39-48. PubMed ID: 19052469
[TBL] [Abstract][Full Text] [Related]
37. Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.
Praiss AM; Miller A; Smith J; Lichtman SM; Bookman M; Aghajanian C; Sabbatini P; Backes F; Cohn DE; Argenta P; Friedlander M; Goodheart MJ; Mutch DG; Gershenson DM; Tewari KS; Wenham RM; Wahner Hendrickson AE; Lee RB; Gray H; Secord AA; Van Le L; O'Cearbhaill RE
Gynecol Oncol; 2023 Jul; 174():213-223. PubMed ID: 37229879
[TBL] [Abstract][Full Text] [Related]
38. The use of the Calvert formula to determine the optimal carboplatin dosage.
van Warmerdam LJ; Rodenhuis S; ten Bokkel Huinink WW; Maes RA; Beijnen JH
J Cancer Res Clin Oncol; 1995; 121(8):478-86. PubMed ID: 7642691
[TBL] [Abstract][Full Text] [Related]
39. A comparison of measured and estimated glomerular filtration rate for carboplatin dose calculation in stage I testicular seminoma.
Quinton A; Lewis P; Ali P; Morgan C; Bertelli G
Med Oncol; 2013; 30(3):661. PubMed ID: 23864250
[TBL] [Abstract][Full Text] [Related]
40. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.
Veal GJ; Errington J; Tilby MJ; Pearson AD; Foot AB; McDowell H; Ellershaw C; Pizer B; Nowell GM; Pearson DG; Boddy AV;
Br J Cancer; 2007 Mar; 96(5):725-31. PubMed ID: 17299395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
